156185-63-6

Basic information

• Product Name: TERT-BUTYL 4-(3-HYDROXYPROPYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE
• Synonyms: 4-(3-HYDROXY-PROPYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-N-BOC-4-(3'-PROPANOL)-PIPERIDINE;TERT-BUTYL 4-(3-HYDROXYPROPYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE;4-(3-Hydroxypropyl)piperidine, N-BOC protected;Tert-butyl 4-(3-hydroxypropyl)tetrahydro-1(2H)-pyridinecarboxylate ,97%;3-(1-Boc-4-piperidyl)-1-propanol;3-(1-(tert-Butoxycarbonyl)piperidin-4-yl)propanol;3-(N-Boc-piperidin-4-yl)propanol
• CAS NO: 156185-63-6
• Molecular Formula: C₁₃H₂₅NO₃
• Molecular Weight: 243.34
• Product Categories: Pyrans, Piperidines &Piperazines;Pyrans, Piperidines & Piperazines;CMLLYL
• Mol File: 156185-63-6.mol

Chemical Properties

• Boiling Point: 339.8 °C at 760 mmHg
• Flash Point: 159.3 °C
• Appearance: /
• Density: 1.029
• Vapor Pressure: 6E-06mmHg at 25°C
• Refractive Index: 1.478
• Storage Temp.: 2-8°C
• PKA: 15.16±0.10(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-(3-HYDROXYPROPYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(3-HYDROXYPROPYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE(156185-63-6)
• EPA Substance Registry System: TERT-BUTYL 4-(3-HYDROXYPROPYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE(156185-63-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 156185-63-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
TERT-BUTYL 4-(3-HYDROXYPROPYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE is used as an intermediate for the production of certain medications due to its ability to be synthesized into biologically active compounds.
Used in Alzheimer's Disease Treatment:
In the field of neurology, TERT-BUTYL 4-(3-HYDROXYPROPYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE is used as a cholinesterase inhibitor for its potential value in the treatment of Alzheimer's disease, helping to improve cognitive function by increasing the levels of acetylcholine in the brain.
Used in Cardiovascular Drug Synthesis:
TERT-BUTYL 4-(3-HYDROXYPROPYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE is utilized in the synthesis of antihypertensive and antiarrhythmic drugs, contributing to the development of medications that help regulate blood pressure and heart rhythm.
Used in Organic Chemistry:
As a reagent in organic chemistry reactions, TERT-BUTYL 4-(3-HYDROXYPROPYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE plays a role in various synthesis processes, facilitating the creation of a range of chemical products.

InChI:InChI=1/C13H25NO3/c1-13(2,3)17-12(16)14-8-6-11(7-9-14)5-4-10-15/h11,15H,4-10H2,1-3H3

Upstream product

• 403802-41-5 tert-butyl 4-(3-hydroxyprop-1-yn-1-yl)piperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 109438-76-8 3-[4]piperidyl-propan-1-ol; toluene-4-sulfonate 
• 165528-85-8 1,1-dimethylethyl 4-(3-oxopropyl)-1-piperidinecarboxylate 
• 162504-75-8 tert-butyl 4-(3-methoxy-3-oxopropyl)piperidine-1-carboxylate 
• 104-58-5 3-piperidinopropan-1-ol 
• 2629-72-3 4-(3-Hydroxypropyl)pyridine 
• 7037-49-2 3-(piperidin-4-yl)propan-1-ol 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 164149-27-3 tert-butyl 4-(3-bromopropyl)piperidine-1-carboxylate 
• 692890-13-4 3-(3-(N-Boc-piperidin-4-yl)-propoxy)-phenylacetic acid 
• 692891-81-9 2-(3-(3-(N-Boc-piperidin-4-yl)-propoxy)-phenyl)-N-(4-pyridin-4-yl-thiazol-2-yl)-acetamide 
• 692883-31-1 2-(3-(3-(piperidin-4-yl)-propoxy)-phenyl)-N-(4-pyridin-4-yl-thiazol-2-yl)-acetamide 
• 692884-29-0 2-(3-(3-(N-methyl-piperidin-4-yl)-propoxy)-phenyl)-N-(4-pyridin-4-yl-thiazol-2-yl)-acetamide 
• 203859-94-3 4-(3-Methanesulfonyloxy-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 203306-85-8 tert-butyl 4-[3-(p-tolylsulfonyloxy)propyl]piperidine-1-carboxylate 
• 165528-85-8 1,1-dimethylethyl 4-(3-oxopropyl)-1-piperidinecarboxylate 
• 692890-07-6 methyl 3-(3-(N-Boc-piperidin-4-yl)-propoxy)-phenylacetate 
• 142374-17-2 4-{3-[4-((S)-2-Benzyloxycarbonylamino-4-diazo-3-oxo-butyl)-phenoxy]-propyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 142408-92-2 methyl 3-(S)-amino>-4-<4-<<piperidin-4-yl>propyl>oxy>phenyl>butanoate 
• 142374-15-0 methyl 2-(S)-amino>-3-<4-<<piperidin-4-yl>propyl>oxy>phenyl>propionic acid ester 
• 1026303-40-1 4-(3-{4-[(S)-2-(Butane-1-sulfonylamino)-3-methoxycarbonyl-propyl]-phenoxy}-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 142408-93-3 4-{3-[4-((S)-2-Benzyloxycarbonylamino-3-carboxy-propyl)-phenoxy]-propyl}-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Catalyst-Free Deaminative Functionalizations of Primary Amines by Photoinduced Single-Electron Transfer

The use of pyridinium-activated primary amines as photoactive functional groups for deaminative generation of alkyl radicals under catalyst-free conditions is described. By taking advantage of the visible light absorptivity of electron donor–acceptor complexes between Katritzky pyridinium salts and either Hantzsch ester or Et3N, photoinduced single-electron transfer could be initiated in the absence of a photocatalyst. This general reactivity platform has been applied to deaminative alkylation (Giese), allylation, vinylation, alkynylation, thioetherification, and hydrodeamination reactions. The mild conditions are amenable to a diverse range of primary and secondary alkyl pyridiniums and demonstrate broad functional group tolerance.

N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE

Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor(LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory disease and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS FOR TREATING NEUROPSYCHIATRIC DISORDERS

The present invention concerns benzodioxane-piperidine with general formula I: wherein notably: R1 represents one or more identical or different substituent(s) on the benzene ring, each independently representing a hydrogen or halogen atom, or a C1-4 alkyl group, or a C1-4 alkoxy group or a C1-4 hydroxyalkyl group or a C1-4 alkylcarbonyl or an alkoxycarbonyl group or an OH group or an SO2R group with R alkyl, or a CN group, or a CF3 group, or an OCF 3 group; n=1, 2 or 3;m=0 or 1, andR2 represents one or more identical or different substituent(s) on the oxazolidinone or morpholinone ring, each independently representing: a hydrogen atom, a C1-4 alkyl group, or a C1-4 alkoxy group, or a C1-4 hydroxyalkyl group, or an alkylcarbonyl group, or an alkoxycarbonyl group, or an alkoxyphenyl group.

Synthesis and in vitro evaluation of tetrahydroisoquinolines with pendent aromatics as sigma-2 (σ2) selective ligands

5-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl)]-2, 3-dimethoxybenzamide 1 is a potent and selective σ2 receptor ligand suitable for further development. A series of new analogues, incorporating a variety of isoquinoline and carboxylic acid moieties, linked together with either a linear or cyclic amine spacer have been synthesised and assessed for their σ1/σ2 binding affinity and selectivity. Compounds with a rigid piperidine spacer gave Ki values for the σ2 receptor between 8.7-845 nM. Changing the configuration of the methoxy groups on the isoquinoline moiety resulted in molecules with σ2Ki values of 4.4-133 nM whereas varying the length and flexibility of the carbon spaces gave σ2Ki values 0.88-15.0 nM, some of the most active, selective σ2 ligands to date. Thus, the flexibility and length of the carbon linker and the carboxylic acid moiety are confirmed to be key to the exceptional binding affinity and selectivity for this active series. Additionally, the incorporation of a halogen on selected carboxylic acid moieties provided a convenient strategy for the introduction of a radiohalogen for applications in pharmacological and imaging studies.

COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.

[4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases

The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.

AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES

The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES

The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES

The present invention relates to substitute thiazole and thiophene derivatives useful as inhibitors of rock and other protein kinaeses. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders, including proliferative, cardiac and neurodegenerative diseases.

2,3-oxidosqualene-lanosterol cyclase inhibitors

The present invention relates to piperidine derivatives useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.